65,437 trials
Crohn Disease
Primary: Percentage of Subjects With at Least One Adverse Event (AE) During the Duration of the Study C87088 (up to 272 Weeks) — 89.6 percentage of subjects
Lung Cancer
Primary: Overall Objective Response — 1; 1; 3; 2 participants
Panic Disorder
Primary: Change in Mean Total Panic Disorder Severity Scale (PDSS) Scores — -5.3; -5.6 units on a scale
Pharmacokinetics
Primary: Number of Participants Who Experienced One or More Adverse Events (AEs) — 4; 5; 5; 5 Participants
Asthma
Primary: FEV1 Percent Predicted — 51.7; 52.6 percent predicted of FEV1
Cerebral Palsy · Hypoxia-Ischemia, Brain
Primary: Number of Survivors With an IQ > 84 — 75; 52 participants
Dietary Carcinogenesis
Primary: AFB1-lysine Adduct (pg/mg) Overtime — 3.77; 4.09; 4.26; 3.00 pg/mg albumin
Hyperinsulinemia · Miscarriages · Pregnancy
Primary: Neonatal Hypoglycemia — 3; 15 neonates
Coronary Artery Disease
Primary: Brachial Artery Flow Mediated Dilation — 1.2 percent change
Lymphoma, T-Cell · Lymphoma, Extranodal NK-T-Cell
Primary: Maximum Tolerated Dose (MTD) of Alemtuzumab — 30 mg
Kidney Transplantation
Primary: Incidence of Acute Rejection (Banff '97) or Antibody Mediated Rejection — 2; 0; 5; 3 participants
Compensated Cirrhosis and Portal Hypertension
Primary: Change From Baseline of the Blood Flow for the Total Renal Arteries (Study Part A (Serelaxin Treatment Group Only)) — 0.438 L/min
Pulmonary Disease, Chronic Obstructive
Primary: FEV1 AUC0-3h Response — -0.006; 0.188; 0.279; 0.293 L — p=<0.0001
Influenza
Primary: Geometric Mean Titers of Influenza Antibodies Before and Following Vaccination With a Quadrivalent Influenza Vaccine — 257; 589; 382; 782 Titers (1/dilution)
Rheumatoid Arthritis
Primary: Correlation Between Beliefs About Medicines Questionnaire (BMQ) Necessity Score and Disease Activity Score Based on 28 Joints Count (DAS28) at Month 12 — -0.06…